Literature DB >> 3930572

Characterization of immunotoxins active against ovarian cancer cell lines.

R Pirker, D J FitzGerald, T C Hamilton, R F Ozols, W Laird, A E Frankel, M C Willingham, I Pastan.   

Abstract

The purpose of the present study was to develop immunotoxins directed against human ovarian carcinoma cells. Four monoclonal antibodies (260F9, 454C11, 280D11, and 245E7) were chosen because they were found to bind to various ovarian carcinoma cell lines. These antibodies were covalently linked to either Pseudomonas exotoxin (PE) or ricin A chain (RTA), and the conjugates were tested against five ovarian cancer cell lines (OVCAR-2, -3, -4, -5; A1847). The ability of the immunotoxins to inhibit both protein synthesis and colony formation was evaluated. Qualitatively similar results were obtained for both types of assays. Usually, PE conjugates were more toxic than their corresponding RTA conjugates. 454C11-PE was very toxic for all ovarian carcinoma lines, whereas 454C11-RTA had low activity. Both 260F9-PE and 260F9-RTA were active in all OVCAR cell lines but not in A1847 cells. 280D11-PE was toxic for OVCAR-4; otherwise, 280D11-PE and RTA conjugates of both 280D11 and 245E7 had little activity. Specificity of immunotoxin action was shown by competition by excess antibody, nontoxicity in nontarget cells, and inactivity of an irrelevant immunotoxin. To investigate the basis of antibody-dependent differences in activity of the various immunotoxins, antibody uptake was studied in OVCAR-2 cells, and the results indicate that antibody internalization is one important factor in the activity of immunotoxins.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930572      PMCID: PMC424036          DOI: 10.1172/JCI112082

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   19.456


  23 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma.

Authors:  G B Feldman; R C Knapp; S E Order; S Hellman
Journal:  Cancer Res       Date:  1972-08       Impact factor: 12.701

3.  Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids. Role of the ricin B subunit demonstrated by reconstitution.

Authors:  R J Youle; D M Neville
Journal:  J Biol Chem       Date:  1982-02-25       Impact factor: 5.157

4.  Immunotoxins: a new approach to cancer therapy.

Authors:  E S Vitetta; K A Krolick; M Miyama-Inaba; W Cushley; J W Uhr
Journal:  Science       Date:  1983-02-11       Impact factor: 47.728

5.  Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells.

Authors:  K Eiklid; S Olsnes; A Pihl
Journal:  Exp Cell Res       Date:  1980-04       Impact factor: 3.905

6.  Chemotherapy by intravenous administration of conjugates of daunomycin with monoclonal and conventional anti-rat alpha-fetoprotein antibodies.

Authors:  Y Tsukada; E Hurwitz; R Kashi; M Sela; N Hibi; A Hara; H Hirai
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

7.  Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies.

Authors:  A E Frankel; D B Ring; F Tringale; S T Hsieh-Ma
Journal:  J Biol Response Mod       Date:  1985-06

8.  Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells.

Authors:  D G Gilliland; Z Steplewski; R J Collier; K F Mitchell; T H Chang; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

9.  Transferrin receptors in human tissues: their distribution and possible clinical relevance.

Authors:  K C Gatter; G Brown; I S Trowbridge; R E Woolston; D Y Mason
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

10.  Enhancement of toxicity of antitransferrin receptor antibody-Pseudomonas exotoxin conjugates by adenovirus.

Authors:  D J FitzGerald; I S Trowbridge; I Pastan; M C Willingham
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 12.779

View more
  21 in total

1.  A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.

Authors:  K Mujoo; R A Reisfeld; L Cheung; M G Rosenblum
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells.

Authors:  U C Wargalla; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

3.  Binding parameters of monoclonal antibodies reacting with ovarian carcinoma ascites cells.

Authors:  M J Mattes; K O Lloyd; J L Lewis
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.

Authors:  Y J Lidor; K C O'Briant; F J Xu; T C Hamilton; R F Ozols; R C Bast
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 5.  Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

Authors:  Francisco J Esteva; Dihua Yu; Mien-Chie Hung; Gabriel N Hortobagyi
Journal:  Nat Rev Clin Oncol       Date:  2009-12-22       Impact factor: 66.675

Review 6.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

7.  A preliminary pharmacokinetic study of 111In-labeled 260F9 anti-(breast cancer) antibody in patients.

Authors:  T W Griffin; F Bokhari; J Collins; M Stochl; M Bernier; M Gionet; D Siebecker; M Wertheimer; E S Giroves; L Greenfield
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 8.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

9.  Internalization of an intact doxorubicin immunoconjugate.

Authors:  L B Shih; D M Goldenberg; H Xuan; H W Lu; M J Mattes; T C Hall
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

10.  The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.

Authors:  C F Scott; V S Goldmacher; J M Lambert; R V Chari; S Bolender; M N Gauthier; W A Blättler
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.